According to the latest market report published by Persistence Market Research, titled ‘Global ADHD Therapeutics Market: Continuous innovation by drug manufacturers and lucrative marketing strategies to fuel the demand for ADHD Therapeutics during the forecast period (2015-2024)’, revenue from the global ADHD therapeutics market is expected to expand at a CAGR of 6.2% during forecast period 2015 – 2024.
The market is segmented based on drug type, age group, distribution channel, and region. On the basis of drug type, the market has been broadly segmented into stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine).
By drug type, the Lisdexamfetamine Dimesylate drug type sub-segment is expected to register highest CAGR of 15.6% in terms of value over the forecast period. The longer effectiveness of the treatment and easier availability is expected to contribute to its growing adoption.
|To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/4222|
The Lisdexamfetamine Dimesylate drug type sub-segment is expected to reach a market value of US$ 5,682.2 Mn by 2024 end. Stimulants are expected to emerge as the most preferred drug type for both patients and physicians globally over the forecast period. The second-most popular drug type sub-segment is Amphetamine, expected to register a CAGR of 4.2% during the forecast period.
Rising prevalence of ADHD owing to the low threshold of diagnostic criteria, increasing awareness regarding ADHD, and shift from ICD-10 to DSM-IV are major factors driving the growth of the global ADHD therapeutics market currently. Other trends driving market growth are increasing concerns among parents and cultural differences towards ADHD, rising ADHD drug usage in adults, and novel drug development.
For Critical Insights On The Attention Deficit Hyperactivity Disorder Therapeutics Market, Request For Customization Here @ https://www.persistencemarketresearch.com/request-customization/4222
Generic drug manufacturers in the global ADHD therapeutics market are focusing on introducing cheaper and effective generic ADHD drugs to increase market share, the post-patent expiry of prescription drugs. Furthermore, adoption of alternative treatment methods and drug abuse are factors hampering the growth of this market.
This report assesses trends driving each market segments and sub-segments and offers analysis and insights into the potential of ADHD therapeutics therapies in specific regions. North America is estimated to dominate the global ADHD therapeutics market, with a maximum value share of the overall market by the end of 2016. By 2024, North America and Europe markets are expected to account for over four-fifths share of the global ADHD therapeutics market revenue. In terms of value, North America is estimated to be the dominant market, registering a CAGR of 5.9% over the forecast period.
For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/4222
Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
- Amedra Pharmaceuticals LLC
- Eli Lilly and Company
- Janssen Pharmaceuticals, Inc.
- Noven Pharmaceuticals, Inc.
- Novartis Pharmaceuticals Corporation
- Celltech Group Ltd.
- Purdue Pharma L.P.
More About the Report –
Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.
The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
According to a report published by Persistence Market Research (PMR), the global animal healthcare market is expected to witness a CAGR of 4.8% from 2017 to 2025. In 2017, the market was worth US$ 30,744.2 Mn and is estimated to rise to a valuation of US$ 44,847.2 Mn by the end of 2025.
According to a new market report published by Persistence Market Research “Global Market Study on Dental Implants – Asia Pacific to Witness Fastest Growth by 2020,” the global Dental implants market was valued at USD 4,508.9 million in 2014 and is expected to grow at a CAGR of 9.7% from 2014 to 2020, to reach an estimated value of USD 7,879.5 million in 2020.
Globally, rising aging population has increases the demand for dental implants in the market. As a result, the market is expected to grow at a CAGR of about 9.7% from 2014 – 2020.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.